The FDA’s final round of clinical trials of the highly-popular hepatitis C vaccine will be held on November 11-12 in Atlanta.
Here are a few things to know about the upcoming round:1.
This year’s clinical trials are expected to last for three to six months.2.
Researchers have already completed a clinical trial involving 7,000 people.3.
The researchers are working to expand the scope of the study to include a larger sample of people.4.
The NIH expects to release data from the study in January 2019.5.
It is expected that there will be a final report in January 2020.6.
There are two rounds of clinical studies in Phase 1.
The first phase, which is expected to enroll about 100,000 participants, will test the vaccine in people with mild-to-moderate-severe hepatitis C. The second phase, expected to start enrolling participants in early 2019, will enroll people with moderate-to, severe-to severe hepatitis C who will be tested in a broader range of settings.7.
The goal of the Phase 1 study is to assess whether the vaccine is safe and effective.
This is the first time that the FDA has given the go-ahead for a Phase 1 clinical trial of the vaccine.8.
The clinical trials will include a “preliminary” stage, which means that participants will be enrolled in the trial for a minimum of two weeks.9.
Researchers will be monitoring how the participants react to the vaccine and how the vaccine interacts with their immune system.10.
Participants will be monitored by the FDA for signs of side effects, including fatigue, nausea, vomiting, or fever.11.
The FDA is looking for participants with mild to moderate-severe hep C to participate in the Phase 2 clinical trials.
Those who have mild to moderately-severe liver disease and those with moderate to severe hep C should be eligible for participation.12.
Participants in the second phase will be eligible to participate if they are at least 65 years old.13.
Participants with moderate and severe liver disease who have not had any serious liver disease will be able to participate.14.
Participants who have moderate to persistent or severe liver damage and who are enrolled in a Phase 3 clinical trial should have symptoms of acute hepatitis C by January 2019 and be monitored for signs and symptoms of the disease.
The remaining participants will have to be monitored until the end of February 2019.15.
Participants are eligible for a $6,500 “surplus” payment if they do not meet all of the criteria for enrollment.16.
Participants have the option to enroll in either a Phase 2 or Phase 3 trial of HCV vaccine.
If they choose to participate, they will receive up to $2,000 for every participant who completes the trial, as well as $2.50 for each additional person they enroll.17.
Participants must complete a questionnaire at the time of enrollment.
It asks questions about their overall health, the extent to which they have recovered from illness, their level of risk for developing other health conditions, and the duration of their illness.18.
The questionnaire will be administered to participants during a phone interview in which they are asked about their personal history, their health and their family history of cirrhosis and liver disease.
Participants may be asked questions about other medications they take, including prescription and over-the-counter medications, vitamins and minerals, and alcohol.19.
Participants can receive up, six, or seven doses of the HCV-A vaccine before enrolling in the study.20.
Participants also will be asked to take a blood sample every four months for 12 months.21.
Participants enrolled in Phase 3 will be expected to be tested for signs or symptoms of cirruvium.
They will receive another dose of the virus when they are tested again in February 2019, or the end, if they don’t have symptoms by January 2020, if a second dose is needed.22.
There will be no other tests for the HC (Hepatitis C) vaccine.23.
Participants participating in the first phase of the trials will be required to take all available doses of hepatitis C medication within two weeks of completing the trial.
Participants testing positive for HCV will be offered a choice between receiving no medication or taking one of the two other HCV medications.
Participants receiving a second round of HC vaccine doses will be treated with the first two HC vaccine rounds.24.
Participants should not get any HCV medication from a healthcare provider during or after the study, and they should not use a medical device or injection to inject HCV into a partner.25.
The vaccine is only available through the FDA and not through retail pharmacies.26.
Participants that have received all doses of HCX vaccine and who have symptoms and/or signs of HCv will be evaluated in the next few weeks.27. The phase